Current Insights into Pasireotide Therapy for Uncontrolled Acromegaly: Biochemical Response, Tumor Reduction, and Glycemic Safety in a Real-World Latin American Cohort
Life · 03.07.2026 · 16 (7) · 1114
DOI: 10.3390/life16071114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life, online erschienen am 03.07.2026. Verfasst von Alin Abreu Lomba und 5 weiteren Autor:innen. Beteiligte Einrichtung: Grupo Interinstitucional de Medicina Interna (GIMI1), Universidad Libre, Cali 760045, Colombia. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Acromegaly is a chronic endocrine disorder caused mainly by GH-secreting pituitary adenomas, leading to excess GH and elevated IGF-1. Although surgery is first-line therapy, many patients require medical treatment, and remission is often not achieved with first-generation somatostatin receptor ligands (SRLs). Pasireotide, a second-generation SRL, offers superior biochemical and tumor control but is associated with hyperglycemia. This study aimed to evaluate real-world outcomes associated with pasireotide treatment in patients with acromegaly inadequately controlled on first-generation SRLs, with IGF-1 normalization as the primary endpoint. Secondary outcomes included GH control, tumor response, and glycemic safety.
Methods
We conducted a historical cohort study of adults with acromegaly treated at Clínica Imbanaco (Cali, Colombia) between 2017 and 2024. Eligible patients had residual tumors and persistently elevated GH and/or IGF-1 levels above the age-adjusted upper limit of normal despite treatment with clinically adequate doses of first-generation SRLs, as well as 12 months of continuous pasireotide treatment and follow-up after pasireotide initiation. Demographic, biochemical, imaging, and glycemic data were collected. Statistical analysis included paired and independent Student’s t-tests, Wilcoxon signed-rank tests, McNemar’s test, and Fisher’s exact test, with significance set at p < 0.05.
Results
Fourteen patients (50% female; mean age 52.1 ± 14.5 years) were included. After 12 months, mean IGF-1 decreased from 2.73 ± 0.73 to 0.99 ± 0.56 × ULN, and 50% achieved IGF-1 normalization. Additionally, 35.7% achieved GH < 1 ng/mL, and 14.3% achieved combined control. Mean tumor diameter decreased by −3.26 mm (95% CI −4.56 to −1.95; p < 0.001). HbA1c increased from 5.56% to 6.05%, while type 2 diabetes mellitus prevalence rose from 14.3% to 35.7%. No patient discontinued pasireotide due to metabolic adverse events.
Conclusions
Pasireotide was associated with favorable biochemical and tumor responses in patients with acromegaly inadequately controlled on first-generation SRLs under real-world conditions. Although treatment was associated with higher HbA1c and increased diabetes incidence, proactive monitoring and early management of hyperglycemia may have supported treatment persistence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Grupo Interinstitucional de Medicina Interna (GIMI1), Universidad Libre, Cali 760045, Colombia.
- Endocrinology Department, Clínica Imbanaco, Cali 760042, Colombia.
- Department of Public Health, Pontificia Universidad Javeriana, Cali 760031, Colombia.
- Clinical Research Center, Clínica Imbanaco, Cali 760042, Colombia.
- Endocrinology Department, Clínica Nueva de Cali, Cali 760044, Colombia.
- Endocrinology Department, IPS Nauru, Cali 760042, Colombia.
ORCID-Profile: David Alexander Vernaza Trujillo, Wilfredo Antonio Rivera-Martínez, Juan S Izquierdo-Condoy
Zitieren
APA
Abreu Lomba, A., Vernaza Trujillo, D. A., Tafur Monje, C. A., Rivera-Martínez, W. A., Mejía Vélez, C. A., & Izquierdo-Condoy, J. S. (2026). Current Insights into Pasireotide Therapy for Uncontrolled Acromegaly: Biochemical Response, Tumor Reduction, and Glycemic Safety in a Real-World Latin American Cohort. Life, 16(7), 1114. https://doi.org/10.3390/life16071114
Vancouver
Abreu Lomba A, Vernaza Trujillo DA, Tafur Monje CA, Rivera-Martínez WA, Mejía Vélez CA, Izquierdo-Condoy JS. Current Insights into Pasireotide Therapy for Uncontrolled Acromegaly: Biochemical Response, Tumor Reduction, and Glycemic Safety in a Real-World Latin American Cohort. Life. 2026;16(7):1114. doi:10.3390/life16071114
BibTeX
@article{AbreuLomba2026,
author = {Abreu Lomba, Alin and Vernaza Trujillo, David Alexander and Tafur Monje, Carlos Andrés and Rivera-Martínez, Wilfredo Antonio and Mejía Vélez, Cesar Augusto and Izquierdo-Condoy, Juan S},
title = {Current Insights into Pasireotide Therapy for Uncontrolled Acromegaly: Biochemical Response, Tumor Reduction, and Glycemic Safety in a Real-World Latin American Cohort},
journal = {Life},
year = {2026},
volume = {16},
number = {7},
pages = {1114},
doi = {10.3390/life16071114}
}
EUVIMED